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Strict regulation of proliferation is vital for development, whereas unregulated cell pro-
liferation is a fundamental characteristic of cancer. The polarity protein atypical protein
kinase C lambda/iota (aPKCλ) is associated with cell proliferation through unknown
mechanisms. In endothelial cells, suppression of aPKCλ impairs proliferation despite hyper-
activated mitogenic signaling. Here we show that aPKCλ phosphorylates the DNA binding
domain of forkhead box O1 (FoxO1) transcription factor, a gatekeeper of endothelial growth.
Although mitogenic signaling excludes FoxO1 from the nucleus, consequently increasing c-
Myc abundance and proliferation, aPKCλ controls c-Myc expression via FoxO1/miR-34c
signaling without affecting its localization. We find this pathway is strongly activated in the
malignant vascular sarcoma, angiosarcoma, and aPKC inhibition reduces c-Myc expression
and proliferation of angiosarcoma cells. Moreover, FoxO1 phosphorylation at Ser218 and
aPKC expression correlates with poor patient prognosis. Our findings may provide a potential
therapeutic strategy for treatment of malignant cancers, like angiosarcoma.
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Cell proliferation is tightly controlled during developmentand in tissue homeostasis, while unrestrained cell divisionis a hallmark of cancer1,2. With stimulation by growth
factors, such as vascular endothelial growth factors (VEGFs),
endothelial cells (ECs), the cells that line the innermost layer of
the vasculature, expand rapidly in a tightly coordinated manner
to form new vessels2–4. Conversely, aberrant EC proliferation is a
driver of numerous diseases and occurs in multiple forms of
vascular tumors, including angiosarcoma, a malignant vascular
neoplasm5.
Forkhead box O1 (FoxO1), an effector of the
phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway, is a key
transcriptional regulator of cell proliferation under the control of
the receptor tyrosine kinase signaling pathway6. Recent work has
highlighted that endothelial growth is regulated by FoxO1
downstream of VEGF-A in a context dependent manner7,8.
VEGF/PI3K/Akt signaling promotes FoxO1 cytoplasmic locali-
zation, resulting in its inactivation8. Cytoplasmically localized
FoxO1 was associated with c-Myc expression and EC prolifera-
tion, and loss of FoxO1 resulted in increased EC proliferation8.
Another work has shown that VEGF-induced EC proliferation is,
instead, suppressed with loss of FoxO1. They also found that
constitutively active FoxO1 does not inhibit EC proliferation in
the liver and the kidney at the adult stage, but leads to lethality
due to heart defects7.
Cell polarity is a fundamental feature of many cells types that is
required for proper tissue function. Conversely, loss of polarity
causes tissue disorganization and excessive cell growth1,9. One of
the key regulators of cell polarization, conserved from worms to
mammals, is atypical protein kinase C (aPKC)10. Disrupted aPKC
exhibits not only polarization defects but also altered cell pro-
liferation in Drosophila and Xenopus models11,12. In mammals,
aPKCλ is often over-expressed and mis-localized in highly
malignant tumors, including ovarian, breast, and lung cancer13–
16. In ECs, loss of aPKCλ leads to hyper-activation of VEGF
signaling but, paradoxically, knockout (KO) mice show impaired
EC proliferation17. However, the molecular mechanism con-
necting aPKC to cell proliferation remains elusive. Here we
provide mechanistic insight into how aPKC regulates endothelial
growth. Our study reveals that aPKC controls physiological and
pathological vascular growth by regulating the transcriptional
activity and abundance of key transcription factors FoxO1 and c-
Myc. Moreover, we show that abnormal aPKC/FoxO1/c-Myc
signaling contributes to excessive EC proliferation in
angiosarcoma.
Results
aPKCλ controls c-Myc expression via FoxO1. Although aPKCλ
is a negative regulator of VEGF signaling, loss of aPKCλ in ECs
results in decreased proliferation17. To begin to understand this
conundrum, we examined the expression of FoxO1 and c-Myc in
the retinal vasculature at postnatal day 6 (P6) in control and EC
specific inducible aPKCλ loss of function (PrkciiΔEC) mice
(Fig. 1a, b). As previously shown, reduced vascular branching was
confirmed in PrkciiΔEC mice17. FoxO1 expression and localization
were indistinguishable between control and PrkciiΔEC mice
(Fig. 1a). In control animals, a strong c-Myc signal was detected
just behind the angiogenic front and in ECs surrounding and
within the vein, where proliferation actively occurs18. However, c-
Myc expression in PrkciiΔEC mice was strongly suppressed
(Fig. 1b). Additionally, we confirmed that c-Myc expression was
also suppressed in human EC after siRNA mediated knockdown
of PRKCI (Supplementary Fig. 1a). We have previously reported
that a gradient of aPKC activity can be observed in the P6 retinal
vasculature, with the highest activity of aPKC observed in the
vascular plexus17. Consistent with our previous report, there was
no signal corresponding to active aPKC (phospho-aPKC) detec-
ted in the tip cells of the angiogenic front, but a jump in the
activity of aPKC could be seen in the EC just behind the leading
edge of the vascular front, where c-Myc was abundantly expressed
(Supplementary Fig. 1b). The strongest signal for activated aPKC
was observed in the more mature vessels of the vascular plexus
(Supplementary Fig. 1b). Nuclear localized FoxO1 was also most
strongly observed in the vascular plexus compared to the angio-
genic front (Supplementary Fig. 1c). To confirm the effect of
aPKC deletion on c-Myc expression just behind the angiogenic
front, we carried out mosaic deletion experiments using an EYFP
Cre reporter mouse line. After mosaic deletion of aPKC due to a
single low dose injection of tamoxifen at P1, c-Myc signal was
significantly reduced in aPKC deficient cells expressing the EYFP
Cre reporter compared to that of non-recombined control EYFP
negative cells within the same retina (Supplementary Fig. 1d, e).
To examine whether the observed alteration in c-Myc
expression upon aPKCλ deletion is mediated via FoxO1, we
generated endothelial specific inducible Prkci/Foxo1 double KO
mice. These double KO mice displayed a striking phenotype
characterized by increased vascular coverage at the distal ends
and associated angiogenic front of only the venous but not
arterial regions (Fig. 1c, d; Supplementary Fig. 2a, b). Consistent
with previous reports, Prkci mutants displayed reduced, and
Foxo1 mutants displayed increased venous vascular coverage
(Fig. 1d; Supplementary Fig. 2a)8,17. Double KO venous vascular
coverage was not significantly different from Foxo1 mutants but
significantly increased compared to Prkci mutants (Fig. 1d;
Supplementary Fig. 2a). Interestingly, relative radial expansion of
the retinal vasculature was modestly decreased in PrkciiΔEC
mutants, but strongly reduced in FoxO1 iΔEC and double KO
mice without showing an additive effect (Fig. 1e; Supplementary
Fig. 2a). Additionally, distinct stumpy hyperdense vascular
regions were observed in ~75% of veins and their associated
angiogenic front of the double knockout retinas (Fig. 1c;
Supplementary Fig. 2a, c), and were also observed in the Foxo1
mutant retina (Supplementary Fig. 2a, c)8. This phenotype
displayed an equal degree of penetrance in both double KO and
Foxo1iΔEC mutants (Supplementary Fig. 2a, c).
We confirmed that c-Myc expression was upregulated in the
retinal angiogenic front of the EC specific FoxO1 mutant mice
(Fig. 1g), and, importantly, the impaired c-Myc expression
observed in the PrkciiΔEC mutant retina EC was rescued with
double KO of Prkci and Foxo1 (Fig. 1f, g). These results suggest
that aPKC controls c-Myc expression via FoxO1 through a
mechanism that does not involve FoxO1 sequestration to the
cytoplasm, as observed during VEGF signaling.
aPKC phosphorylates FoxO1 at Ser218. To understand how
aPKCλ affects c-Myc expression via FoxO1, we investigated
whether aPKCλ can phosphorylate FoxO1. Purified full-length
FoxO1 was effectively phosphorylated when incubated with
recombinant aPKCλ (Fig. 2a). To identify aPKCλ-dependent
phosphorylation sites in FoxO1, phosphorylated FoxO1 was
analyzed using a phosphoproteomic approach. Mass spectro-
metry analysis identified serine 218 (Ser218) as the predominant
phosphorylation site in FoxO1, conserved from worms through
all mammalian FoxOs and located within its DNA-binding
domain (DBD) (Supplementary Fig. 3a, b). Mutating Ser218 to
Ala almost completely abolished FoxO1 phosphorylation by
aPKCλ in vitro, confirming that Ser218 is the major phosphor-
ylation site (Fig. 2a). To examine the phosphorylation of FoxO1
at Ser218 in vivo, we generated two antibodies that specifically
recognize Ser218-phosphorylated (pSer218) FoxO1. The specifi-
city of the antibody was assessed by western blot analysis. GST-
FoxO1 DBD phosphorylated by purified aPKCλ in vitro was
specifically detected by anti-pSer218 antibodies in a dose
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dependent manner (Supplementary Fig. 3c). Ectopic expression
of aPKCλ in cultured ECs resulted in a marked increase in the
reactivity of the pSer218-FoxO1 antibodies (Fig. 2b), whereas
treatment of the cells with a myristoylated aPKC pseudosubstrate
inhibitor (aPKC kinase inhibitor) diminished pSer218 reactivity
(Fig. 2b). We next used these antibodies to analyze Ser218
phosphorylation of FoxO1 during angiogenesis. Consistent with
our analyses of aPKC activity in the retinal vasculature, pSer218-
FoxO1 immunofluorescent signals detected with both antibodies
were below detectable levels in the tip cells of the angiogenic
front, but a signal could be detected in the EC just behind the
leading edge of the angiogenic front, and the strongest signal was
observed in the more established and remodeled vessels of the
central retina (Fig. 2c; Supplementary Fig. 3d). On the other
hand, immunoreactive signal against total FoxO1 distributed
evenly throughout the whole retinal vasculature (Fig. 1a; Sup-
plementary Fig. 1c). Moreover, signal corresponding to pSer218
in FoxO1 was strongly decreased in PrkciiΔEC mice and Fox-
o1iΔEC mice (Fig. 2d, e). The immunofluorescent signal for
pSer218-FoxO1 in the vascular plexus of P6 retina was observed
in both cytoplasmic and nuclear compartments (Fig. 2f). Taken
together, we conclude that aPKCλ phosphorylates FoxO1 at
Ser218 in ECs in vitro and in vivo.
aPKCλ controls the DNA-binding ability of FoxO1 but not its
localization. The PI3K/Akt signaling pathway controls the
nuclear localization of FoxO1 via phosphorylation at Thr24/
Ser256/Ser319, which is believed to be a major FoxO1 regulatory





















































































































































































































Fig. 1 aPKCλ controls c-Myc abundance via FoxO1. a Staining of FoxO1 and isolectin-B4 (IB4) in PrkciiΔEC and control mouse retina at postnatal day (P)6.
Staining is representative of 3 animals of each genotype; Scale bar represents 200 μm. b Staining of c-Myc and IB4 in PrkciiΔEC and control mouse retina at
P6. Higher magnification images of indicated areas presented on the right; Staining is representative of 3 control and 7 KO retinas; Scale bar in the left
panel represents 200 μm. Scale bar in the higher magnification image represents 50 μm. c IB4 staining of Prkci/Foxo1iΔEC and control mice at P6. Bottom
panel is higher magnification image of indicated area from the upper panel of each genotype. Images are representative of > 10 animals of each genotype;
Scale bar in the upper panel and the lower panel represents 250 μm and 100 μm, respectively. d Quantification of relative ratio of vascular coverage in the
venous region; line represents median, whiskers representing range; one-way ANOVA Bonferroni post-hoc analysis; *p < 0.05; ****p < 0.0001; n.s p > 0.05;
(n≥ 10). e Quantification of relative radial expansion of the retinal vasculature at P6; line represents median, whiskers representing range; one-way
ANOVA Bonferroni post-hoc analysis; n.s. p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; (n≥ 10). f c-Myc and IB4 staining in Prkci/Foxo1iΔEC
and control P6 retina. Staining is representative of > 8 animals of each genotype; Scale bar represents 100 μm. g Quantification of c-Myc signal intensity of
P6 vascular front; Data represent mean ± S.E.M. two-tailed unpaired t-test *p < 0.05; **p < 0.01 (n≥ 3)
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FoxO1 by aPKCλ controls its nuclear localization, we separated
the nuclear and cytosolic compartments from ECs. Consistent
with the in vivo observation in mouse retina, KD of PRKCI did
not affect the sub-cellular localization of FoxO1 in cultured ECs
(Supplementary Fig. 4a). Furthermore, overexpression of aPKCλ
did not have any effect on the nuclear localization of FoxO1
(Supplementary Fig. 4b). Active aPKCλ localized only within the
cytosol (Supplementary Fig. 4b).
To gain insight into the consequences of the phosphorylation
of FoxO1 by aPKCλ, we looked at the location of Ser218 using the
published structure of DNA bound FoxO119. Ser218 is located
within the FoxO1 DBD (Fig. 3a), and is predicted to have a
critical role in regulating the interaction of FoxO1 with the
phosphate backbone of DNA. To confirm this, we substituted
Ser218 to aspartic acid to mimic phosphorylation (S218D) and
assayed the ability of the mutant to bind DNA using an
electrophoretic mobility shift assay. Purified FoxO1 DBD bound
to the canonical FoxO DNA-binding element (DBE) as previously
reported19. However, the FoxO1 S218D DNA-binding domain
was unable to bind to this sequence (Fig. 3b). To confirm that the
abolition of DNA-binding induced by aPKC dependent phos-
phorylation has an effect on FoxO1 function in cultured cells, we
carried out Luciferase assays in HEK293 cells using the FoxO-
responsive 6xDBE luciferase construct. High luciferase activity
could be induced after overnight serum starvation (SS) as a result
of FoxO nuclear localization. Treatment of the cells with aPKC
kinase inhibitor under these conditions significantly enhanced
luciferase activity, suggesting that endogenous FoxOs transacti-
vates the 6xDBE reporter more effectively when aPKC is inhibited
(Fig. 3c). Mutation of all the Akt phosphorylation sites into
alanine promotes nuclear localization of FoxO1 thereby promot-
ing constitutive activation (FoxO1-CA)6. While overexpression of
FoxO1-CA induced high luciferase activity of the 6xDBE reporter,
FoxO1-CA-S218D (FoxO1-CA/D) did not (Fig. 3d). Given the
predominant localization of aPKCλ within the cytosol (Supple-
mentary Fig. 4b), we used wild-type FoxO1 with another
luciferase construct containing a 479 bp region of the carboxy-
terminal domain RNA polymerase II polypeptide A small
phosphatase 2 (CTDSP2) promoter which contains a known
FoxO binding site20. Overexpression of wild-type FoxO1 was able
to enhance luciferase activity without SS, however, co-expression
of aPKCλ with FoxO1 suppressed it (Fig. 3e). A reporter
construct carrying a point mutation within the FoxO binding
sequence of the CTDSP2 promoter region had significantly
reduced luciferase activity in all conditions (Fig. 3e). These results
suggest that aPKCλ inhibits FoxO1 activity without dynamically
affecting its cellular localization.
We further investigated the significance and role of FoxO1
phosphorylation by aPKCλ using chromatin immunoprecpita-
tion. FoxO1 has been shown to interact with target gene
promoters in a DNA-binding dependent or independent
manner21. As such, we used primers to amplify precipitated
chromatin from p27, a DNA-binding dependent FoxO1 direct
target gene22, and cyclin D1, an indirect target gene21. FoxO1-CA
but not FoxO1-CA/D formed a complex with the p27 promoter
(Fig. 3f). In contrast, both FoxO1-CA and FoxO1-CA/D were
bound to the promoter of cyclin D1 (Fig. 3g). Thus, these results





















































































Fig. 2 aPKCλ phosphorylates FoxO1 at Serine 218. a Phosphorylation of FoxO1 by aPKCλ in vitro. Radioactive proteins were detected by autoradiography
(AR). Autophosphorylation of aPKCλ is indicated with asterisk. Total protein is shown with Coomassie Brilliant Blue (CBB). b Western blot detection of
pSer218 with an anti-pSer218-FoxO1 antibody in cultured ECs overexpressing aPKCλ with and without aPKC inhibitor treatment. c Staining of pSer218 using
an anti-pSer218-FoxO1 antibody and isolectin-B4 in P6 control mouse retina. Arrowheads indicate the position of tip cells and dashed line indicates
approximate threshold where pSer218-FoxO1 is detectable; Staining is representative of 6 animals examined; Scale bar represents 100 μm. d Staining of
pSer218 using an anti-pSer218- FoxO1 antibody and IB4 in PrkciiΔEC and control P6 retina vascular plexus. Staining is representative of 3 animals of each
genotype; Scale bar represents 50 μm. e Staining with anti-pSer218-FoxO1 antibody and IB4 in Foxo1iΔEC and control P6 retina vasculature. Staining is
representative of 3 animals of each genotype; scale bar represents 25 μm. f Phosphorylation of FoxO1 at Ser218 in control P6 retina vascular plexus
detected with anti-pSer218-FoxO1, anti-VE-cadherin, DAPI (lower panels), and IB4 (upper panels). Staining is representative of 6 animals examined; Scale
bar represents 10 μm
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regulates its DNA-binding ability without affecting FoxO1
dynamic localization and selectively determines the direct
interaction of FoxO1 with its target gene promoters.
aPKCλ phosphorylation of FoxO1 controls c-Myc via miR-34c
expression. We next addressed the molecular mechanism
underlying reduced c-Myc expression under aPKCλ loss-of-
function conditions. Previous work has established multiple
regulatory pathways for the control of c-Myc expression by FoxO
transcription factors including the ubiquitin ligase Fbxw7, the
transcriptional repressor Mxi1, and two micro-RNAs (miRNAs),
miR-34c and miR-1458,23–27. The transcription of Fbxw7, Mxi1,
and miR-145 was not altered in PRKCI KD ECs (Supplementary
Fig. 5a, b). In contrast miR-34c expression was significantly
upregulated in PRKCI KD ECs and in the PrkciiΔEC mutant
retinal vasculature (Fig. 4a, b). The expression of miR-34c was
also found to be upregulated after overnight treatment of EC with
aPKC kinase inhibitor, indicating that aPKC regulation of miR-
34c is kinase activity dependent (Fig. 4c). The promoter region of
MIR34C contains a FoxO DBE consensus sequence and FoxO
binding to this position has previously been shown to induce
miR-34c expression25. Using chromatin-immunoprecipitation,
we confirmed that FoxO1-CA but not FoxO1-CA/D could sig-
nificantly bind this region of the miR-34c promoter in cultured
ECs (Fig. 4d). We then examined whether aPKCλ modulation of
c-Myc abundance is controlled by miR-34c. The injection of an
anti-miR-34c inhibitor into newborn pups restored the
compromised c-Myc expression and vascular defects observed in
P6 PrkciiΔEC mutant retinal vasculature upon tamoxifen induced
gene inactivation (Fig. 4e–g). Consistently, double KO of Prkci
and Foxo1 normalized the upregulated miR-34c expression
observed in the Prkci mutant retina (Supplementary Fig. 5c).
Constitutively nuclear FoxO1 has been shown to suppress c-Myc
expression as well as genes involved in c-Myc signaling, thereby
controlling cell cycle and metabolism in ECs8. To gain further
insight into the role of aPKCλ in c-Myc signaling, we examined
expression of these genes. Gene expression of Cdk4, cyclin-B2,
enolase-1, FASN, and LDHB was suppressed in aPKC KD ECs,
while expression of genes encoding cyclin-D1, LDHA, cyclin-D2,
and PKM2 was not affected (Fig. 4h). Of note, the transcriptional
regulation of cyclin-D1, and cyclin-D2 genes by FoxO1, are
independent of its DNA-binding activity21. These results suggest
that loss of aPKCλ selectively affects transcription of target genes
that are FoxO1 DNA-binding dependent, including miR-34c and
c-Myc-signaling genes.
aPKCλ/FoxO1 signaling axis in active in angiosarcoma. aPKCλ,
well known as a cell polarity factor, is over-expressed in multiple
types of malignant tumors13,28,29. Surprisingly, apical basal
polarization visualized by immunoreactive signals against anti-
podocalyxin and collagen IV antibodies did not exhibit clear
differences between control and PrkciiΔEC mice (Supplementary
Fig. 6a). While VE-cadherin and junction adhesion molecule A



























































































































































































Fig. 3 aPKCλ regulates FoxO1 DNA binding via Serine 218 phosphorylation. a Structural depiction of DNA bound FoxO1 DNA-binding domain. FoxO1
(green) and DNA (yellow). Position of Ser218 indicated. b Electrophoretic mobility shift assay with FoxO DBE consensus binding sequence-containing DNA
using GST-FoxO1 DBD and GST-FoxO1 DBD S218D. Arrowhead indicates shifted DNA. NC, negative control. c The effect of aPKC inhibition on endogenous
FoxO1 activity examined with the 6xDBE-luciferase vector. Data represents mean ± S.E.M. two-tailed unpaired t-test ***p < 0.001 (n= 3). d FoxO1 activity
examined with the 6xDBE-luciferase vector and FoxO1-CA or FoxO1-CA/D mutants. Data represents mean ± S.E.M. two-tailed unpaired t-test ***p < 0.001
(n= 3). e The effect of aPKCλ overexpression on FoxO1 activity was examined with CTDSP2-luciferase vectors. The CTDSP2-luciferase construct either
contains the WT CTDSP2 promoter sequence (see materials and methods) or the mutant version where a point mutation was introduced in the FoxO
binding sequence. Data represents mean ± S.E.M. two-tailed unpaired t-test ***p < 0.001 (n= 4). f Chromatin-immunoprecipitation (ChIP) of p27kip1 DNA-
binding-dependent regulatory region with FoxO1-CA or FoxO1-CA/D in HUVEC. Data represents mean ± S.E.M. one-way ANOVA with Bonferroni post-hoc
analyses; ***p < 0.001; ns p > 0.05. (n= 3) g ChIP of a known Cyclin-D1 DNA-binding-independent regulatory region with FoxO1-CA or FoxO1-CA/D in
HUVEC. Data represents mean ± S.E.M. one-way ANOVA with Bonferroni post-hoc analyses ***p < 0.001 (n= 4)
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defects in PrkciiΔEC mutant mice, claudin 5 expression and
transcription were compromised in EC specific aPKCλ loss of
function mice (Supplementary Fig. 6b-d). Claudin 5 is a tran-
scriptional target of FoxO1 and a marker of angiosarcoma cells
within transformed lesions30,31. Angiosarcoma is a highly
malignant tumor characterized by rapidly proliferating,
extensively infiltrating anaplastic cells derived from ECs. C-Myc
has been reported to be over-expressed in angiosarcoma5, and
simultaneous conditional inactivation of all three isoforms of
FoxO in mice lead to the development of lethal angiosarcoma32.
Thus, we hypothesized that the aPKCλ/FoxO1 signaling axis
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immunostaining on EC-derived tumor tissues from cases of pri-
mary non-radiation-induced angiosarcoma and, as a non-
malignant control, the lobular capillary hemangioma, pyogenic
granuloma. Co-immunostaining was carried out with an anti-VE-
cadherin antibody, in order to identify the angiosarcoma or
pyogenic granuloma cells in transformed lesions33, along with
anti-c-Myc, FoxO1, aPKCλ, or pSer218-FoxO1 antibodies. Con-
sistent with previous studies5,34, 16 of 18 angiosarcoma samples
showed modestly or highly elevated c-Myc expression compared
to untransformed cells in the surrounding tissue and in pyogenic
granuloma (Fig. 5a, Supplementary Fig. 7a; Supplementary
Table 1). It has recently been shown that a cytoplasmic cleavage
product of Myc, known as Myc-nick, can be detected by specific
c-Myc antibodies, but not the commonly used mouse monoclonal
9E10 c-Myc antibody35. Due to the strong cytoplasmic signal
observed by immunostaining in the angiosarcoma samples, we
performed a western blot on tissue sections from an angio-
sarcoma patient and confirmed that two bands could be detected
by western blotting analysis, with the lower band matching the
molecular weight reported for Myc-nick (Supplementary Fig. 7b).
Additionally, high-level c-Myc amplification has been observed in
radiation-induced angiosarcoma and has also been reported to be
a rare event in highly overexpressing c-Myc cases of primary
angiosarcoma36,37. Of the highly c-Myc overexpressing patients
in our study (++ or+++ scoring) a single patient (#11) was
found to have c-Myc amplification by FISH. Despite an estab-
lished mutual antagonism between FoxO1 and c-Myc8, 14 of 18
angiosarcoma samples showed strong FoxO1 expression, whereas
FoxO1 expression in pyogenic granuloma samples was low
(Fig. 5b; Supplementary Fig. 7; Supplementary Table 1). More-
over, 14 of 18 angiosarcoma samples showed clear or partial
nuclear localization of FoxO1 with strong protein expression
(Fig. 5b; Supplementary Fig. 7; Supplementary Table 1). aPKCλ
was highly expressed and mis-localized from cell-to-cell contact
sites in 24 of 39 angiosarcoma samples, but not pyogenic gran-
uloma samples (Fig. 5c; Supplementary Fig. 7; Supplementary
Table 1), a pattern that is often observed in malignant cancers28.
Importantly, a strong signal corresponding to pSer218-FoxO1
was confirmed in 28 of 39 angiosarcoma samples, but not pyo-
genic granuloma (Fig. 5d; Supplementary Fig. 7; Supplementary
Table 1). Ki67 staining was carried out on 16 patient samples and
a Ki67 index was calculated. When classified into Ki67 high (44%
(7/16)) and low (56% (9/16)) groups, an association could be
found between Ki67 expression, c-Myc (p= 0.0014; Chi square
test for trend), and aPKC (p= 0.0271; Chi square test for trend),
but not FoxO1 (p= 0.0536; Chi square test for trend) expression
level. The angiosarcoma patients were also classified into strong-
or weak-aPKC expressing groups and pSer218 positive- or
negative-groups, and we compared their survival time using a
Kaplan–Meier analyses. The survival time of the low-aPKC
expressing group and the pSer218-FoxO1 negative group were
significantly longer than that of the high-aPKC and pSer218-
FoxO1-positive groups respectively (Fig. 6; Supplementary
Table 1). These results indicate the correlation of FoxO1 phos-
phorylation at Ser218 by aPKC with angiosarcoma malignancy.
To further link the expression level of aPKCλ and c-Myc with
pathologic EC proliferative capacity, we employed two different
patient-derived angiosarcoma cell lines, ISO-HAS-B and AS-M38,39.
Previous work has found that ISO-HAS-B, but not AS-M, cells are
tumorgenic when injected into immune-compromised mice38,39.
Proliferation of these cell lines was measured using BrdU
incorporation, and ISO-HAS-B proliferation was elevated compared
to primary cultured ECs, whereas that of AS-M was reduced
(Supplementary Fig. 8a). Moreover, expression levels of aPKCλ, c-
Myc, and pSer218-FoxO1 in ISO-HAS-B were higher than that of
primary cultured ECs, while expression of all in AS-M was low
(Supplementary Fig. 8b). Additionally, aPKC was mis-localized
from EC-EC junction sites in ISO-HAS-B cells (Supplementary
Fig. 8c). The anti-rheumatoid agents aurothioglucose (ATG) and
aurothiomalate (ATM) block the binding of PAR-6 and aPKCλ
thereby impairing aPKCλ activation40,41. ATG and ATM inhibit
non-small lung cancer growth and are in an ongoing clinical
trial14,40–43. Pharmacological inhibition of aPKC activity in ISO-
HAS-B using ATG, ATM, and aPKC kinase inhibitor suppressed
FoxO1 phosphorylation and c-Myc expression in a dose dependent
manner, and reduced proliferation (Fig. 7a, b; Supplementary
Fig. 8d-f). aPKC KD or treatment with aPKC inhibitor in ISO-
HAS-B cells induced miR-34c expression, and the treatment of ISO-
HAS-B cells with anti-miR-34c inhibitor induced c-Myc expression
and proliferation (Fig. 7c, d; Supplementary Fig. 8g; 9a). In addition,
FoxO1-CA mutant expression in ISO-HAS-B cells suppressed c-
Myc abundance examined by immunofluorescence, as expected,
whereas c-Myc levels in FoxO1-CA/D expressing cells was not
significantly different from non-transfected neighboring cells, and
significantly higher than that of FoxO1-CA expressing cells (Fig. 7e).
Both constructs reduced proliferation in ISO-HAS-B cells compared
to non-transfected neighboring cells, though FoxO1-CA/D dis-
played a significantly increased proliferation compared to the
FoxO1-CA mutant (Fig. 7f). Importantly, when ISO-HAS-B were
treated with aPKC inhibitor after FoxO1 KD, miR-34c expression
was normalized, confirming the requirement of FoxO1 expression
for aPKC dependent miR-34c expression (Supplementary Fig. 9a).
Unexpectedly, FoxO1 KD alone in ISO-HAS-B cells lead to reduced
c-Myc expression and proliferation, and increased miR-34c
expression (Supplementary Fig. 9a-c). No additive effects were
observed with aPKC inhibitor treatment under these conditions.
Thus, it appears that the ability of FoxO1 to bind to DNA is
important for regulating miR-34c and c-Myc expression in ISO-
HAS-B, but its DNA-binding-independent functions are sufficient
to suppress proliferation. Altogether the results in the angiosarcoma
patient samples and cell line indicate that high aPKC expression
and mislocalization, and the resulting FoxO1 phosphorylation are
involved in malignant EC proliferation by controlling c-Myc
expression.
Fig. 4 aPKCλ regulates c-Myc abundance and signaling via miR-34c. a Expression of miR-34c in control or PRKCI KD siRNA treated HUVEC. Data represent
mean ± S.E.M. two-tailed unpaired t-test *p < 0.05 (n= 5). b Expression of miR-34c in PrkciiΔEC and control P6 retina. Data represent mean ± S.E.M. two-
tailed unpaired t-test *p < 0.05 (n≥ 8). c Expression of miR34c after overnight serum starvation with and without aPKC kinase inhibitor treatment in
HUVEC; Data represents mean+ /- S.E.M., Mann Whitney test; **p < 0.01 (n≥ 8). d ChIP of FoxO1-CA and FoxO1-CA/D from the FoxO1 binding site of
the miR-34c promoter region in HUVEC. Data represent mean ± S.E.M. one-way ANOVA with Bonferroni post-hoc analyses; ns p > 0.05; *p < 0.05 (n= 4).
e Staining of c-Myc (green) and IB4 (red) with c-Myc channel alone in right panels in P6 PrkciiΔEC and control mouse retina after treatment with anti-miR-
34c or scrambled control. Representative staining of > 3 animals of each genotype and treatment; Scale bar represents 100 μm. f Percentage of c-Myc
positive EC cells per field (upper) and endothelial cell coverage region in P6 retina of PrkciiΔEC after treatment with anti-miR-34c or scrambled control. Data
represent mean ± S.E.M. two-way ANOVA with Bonferroni post-hoc analyses; **p < 0.01; *p < 0.05; ns p > 0.05 (n= 3–5). g IB4 (red) and ERG1/2/3
(green) staining in the P6 retina of PrkciiΔEC after treatment with anti-miR-34c or scrambled control. Representative staining of > 3 animals of each
genotype and treatment; Scale bar represents 200 μm. h Relative expression of FoxO1-regulated genes involved in c-Myc signaling measured by RT-PCR in
HUVEC. Data represent mean ± S.E.M. two-tailed unpaired t-test ns p > 0.05; *p < 0.05; **p < 0.01 (n≥ 3)
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Discussion
Here we found that aPKCλ directly controls FoxO1 activity via
phosphorylation in a manner independent of its localization,
resulting in modulation of c-Myc expression (Supplementary
Fig. 10). We establish that this pathway regulates c-Myc expres-
sion during developmental angiogenesis and in malignant endo-
thelial neoplasia. We observed that FoxO1 and c-Myc were highly
expressed in the majority of angiosarcoma patient samples,
despite known mutual antagonism between these two transcrip-
tion factors (Supplementary Table 1; Supplementary Fig. 7).
Furthermore, aPKCλ expression was high and mis-localized from
cell-to-cell junction sites in most of the cases observed. Impor-
tantly, FoxO1 Ser218 was highly phosphorylated in many of the
patients. Single or double deletion of the three FoxO isoforms,
FoxO1, FoxO3, and FoxO4, in mice has been found to result in
tissue specific development of hemangiomas, whereas, only
simultaneous deletion of all three isoforms resulted in lethal
angiosarcoma32. Consistent with these observations, the pre-
dominant aPKCλ dependent FoxO1 phosphorylation site is
conserved in all of the mammalian FoxOs.
Given this critical role of PKCλ activity in FoxO1 regulation, it
will be important to determine the relevant regulators that act
further upstream. Of the numerous direct and indirect molecular
interactions with PKCλ known, the association of the PAR-3/
PAR-6/aPKC polarity complex to junctional proteins and, in
particular, cadherin family cell adhesion molecules are note-
worthy10. Junctions in more established vessels have presumably
higher stability and might sustain or recruit more complexes
containing active aPKC. Indeed, it has been shown that PKCλ
activation is impaired in VE-cadherin loss of function in vitro and
in vivo 17,44, suggesting that junction formation and maturation is
a trigger of PKCλ activity. However, it has been also reported that
the VE-cadherin-associated polarity complex lacks aPKC in cul-
tured ECs45. Future work will have to address the connections
between aPKC, junctional proteins and other potential regulators.
We demonstrated that angiosarcoma proliferation and c-Myc
expression were reduced by treatment with aPKC kinase inhibi-
tors ATG, ATM, and aPKC pseudosubstrate inhibitor. Previous
work has found that the aPKC pseudosubstrate inhibitor used in
this study can be somewhat non-specific in certain cellular con-
texts, and is not capable of inhibiting a splice variant of aPKC
(PKM)46. Despite this, in our experiments, it appears to be
working through aPKC for it could reproduce results obtained
both with genetic inactivation, siRNA mediated knockdown, and
other known aPKC inhibitors.
Our results in the angiosarcoma cell line revealed an unex-
pected increase in miR-34c expression and decrease in c-Myc
expression and proliferation when FoxO1 was knocked down.
This may indicate the potential importance of FoxO in angio-
sarcoma homeostasis. FoxO proteins are known to interact with
p53, and this interaction regulates the expression of specific target
genes and the activity of both transcription factors47–49. P53 is
known to regulate miR-34c expression in transformed cells50 and






































































































































Fig. 5 aPKCλ is involved in vascular tumor malignancy. a Staining of c-Myc, b FoxO1, c aPKC, or d pSer218-FoxO1 (all red channel) and VE-cadherin (green)
with Hoechst 33342 (blue) in malignant angiosarcoma (upper panels) and benign pyogenic granuloma (lower panels) tissue samples. Higher magnification
fields are indicated with dashed boxes. Box 1 indicates VE-Cadherin positive regions and box 2 indicates VE-cadherin negative regions. Scale bar in the left
panels represents 50 μm. Scale bar in the higher magnification field represents 10 µm
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Expression of p53 has also been demonstrated in ISO-HAS-B
cells54. Therefore, the decreased expression of c-Myc with FoxO1
KD in ISO-HAS-B cells may be due to complexity in the aPKC/
FoxO/miR-34c/c-Myc signaling axis under these conditions and
will be examined further in the future.
Although angiosarcoma is an EC-derived tumor and over-
expresses both VEGF-A and VEGF receptors (VEGFRs), the
effect of anti-VEGF reagents including Bevacizumab and Sor-
afenib are limited55,56. While a recent study has shown that
chemoradiotherapy with taxane may be an effective treatment for
angiosarcoma, the prognosis for these patients is very poor57.
Here we were able to show the association between aPKC
expression level and the presence of pSer218-FoxO1 staining and
patient survival and that aPKC inhibitors can affect angiosarcoma
proliferation in vitro, hence, our results present a potential
diagnostic strategy and may open a therapeutic opportunities for
angiosarcoma.
aPKCλ expression is a prognostic marker in many malignant
cancers including ovarian, breast, and lung with increased
expression correlating with poor patient outcomes13–16. Con-
versely, FoxO transcription factors are tumor suppressors58.
Nuclear localized FoxO transcription factors are known to induce
cell cycle arrest, DNA repair, and apoptosis58. Supporting their
role as tumor suppressors, degradation of FoxOs is observed in
oncogenesis in human patients59 and constitutive nuclear exclu-
sion of FoxOs is assumed to promote tumor formation58. Indeed,
constitutive activation of the PI3K/Akt pathway caused by
mutation in Ras small GTPase, PTEN, a negative regulator of
PI3K, and PI3K/Akt itself is observed in many types of cancer60.
Consequently, FoxO nuclear exclusion as a result of PI3K/Akt
mutation has been observed in ovarian cancer, breast cancer, and
glioblastoma22,61,62. Additionally, many conventional anti-cancer
therapies, including tyrosine kinase inhibitors, indirectly target
FoxO activation63. In fact, treatment with tyrosine kinase inhi-
bitors has been shown to induce nuclear translocation of FoxOs
in a murine model of chronic myeloid leukemia, resulting in the
induction of apoptosis64. Despite this established role as tumor
suppressors, several drug resistant tumor cell lines derived from
breast cancer and leukemia patients display FoxO overexpression
and nuclear localization65–67. Moreover, elevated FoxO1 expres-
sion and its nuclear localization were observed in taxane-induced
drug resistance in ovarian cancer patients68. Thus, nuclear loca-
lized FoxO in specific types of drug resistant tumors could be
selectively inactivated by aPKCλ phosphorylation and therefore
targeted therapy for the FoxO/aPKCλ signaling axis identified
here may be useful.
Methods
Human patient samples. Samples were obtained after ethical approval by the
institutional Review Board at MD Andersion Cancer Center, the Institutional
Review Board at Hokkaido University Hospital, or the ethics committee of
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical
Sciences, and Okayama University Hospital respectively.
Mice. Experiments involving animals were conducted in accordance with institu-
tional guidelines and laws, and following the protocols approved by the local animal
ethics committees and authorities (Regierungspraesidium Darmstadt). Pdgfb-iCre
transgenic mice were bred into a background of animals containing a loxP-flanked
Prkci17 or loxP-flanked Foxo18 or both. Cre activity in male and female neonatal
mice was induced by intra-peritoneal injection of tamoxifen (1mg/ml in ethanol/
peanut oil, Sigma, T5648) of 50 µl from P1–P317. The phenotype of the mutant mice
was analyzed at P6 and tamoxifen injected Cre− littermates were used as controls.
For mosaic deletion analysis, PrkciiΔEC mice were crossed with B6.129 × 1-Gt
(ROSA)26Sortm1(EYFP)cosIJ fluorescent reporter mice. A single dose of tamoxifen
(0.1 mg/mL) was injected into male and female neonatal mice on P1.
Cell lines and primary cultures. Pooled human umbilical vein endothelial cells
(HUVECs) were purchased from Pelobiotech (Frankfurt, Germany) and cultured
in EGM-2 medium (Lonza; Basel, Switzerland). HUVECs were used between
passage 1 and 5. HEK293 cells were obtained from the American Type Culture
Collection (LGC Standards, Molsheim Cedex, France) and cultured in DMEM
(Sigma) with 10% fetal bovine serum (FBS; Biochrom GmbH, Berlin, Germany), 2
mM L-glutamine (Gibco, Invitrogen, Life Technologies; Darmstadt, Germany),
100 IUml−1 penicillin, and 100 mg/ml streptomycin. Angiosarcoma cell lines ISO-
HAS-B and AS-M were provided by Dr. Mikio Masuzawa and Dr. Ronald E. Unger
and were cultured in Endothelial cell growth medium MV (PromoCell; Heidelberg,
Germany).
Gene knockdown and overexpression strategies. Oligonucleotide siRNA
duplexes were purchased from GE Healthcare Dharmacon inc. SMART-pool ON-
TARGET plus FOXO1 (see sequences Supplementary Table 2) and ON-TARGET
plus PRKCI siRNA or scrambled control were transfected into HUVECs using
Oligofectamine (Invitrogen) according to the manufacturer’s instructions. Cells
were analyzed 48 h post transfection. For overexpression of proteins in HUVECs,
the indicated plasmids were transfected into the cells with Jet-PEI-HUVEC
(Polyplus; Illkirch, France) according to the manufacture’s instructions and ana-
lyzed 24 h post transfection.
Knockdown of aPKCλ (PRKCI) or FOXO1 was achieved using the same
oligonucleotide siRNA duplexes in ISO-HAS-B cells after transfection with
Lipofectamine-2000 (Invitrogen) according to the manufacturer’s instructions.
Cells were analyzed 48 h post transfection for aPKCλ KD. For aPKC inhibitor
treatment after FoxO1 KD inhibitors were added 24-32 h post transfection and
analyzed 48 h post transfection. MiR-34c inhibition in ISO-HAS-B cells was
achieved by adding anti-miR-34c-5p or anti-miR scrambled control miRCURY
LNA Pwr inhibitor (Exiqon) directly to the cell culture medium followed by
analysis after 48 h of incubation. Overexpression was also carried out using
Lipofectamine-2000 and the indicated plasmids, with analysis 24 h post
transfection.
For overexpression of exogenous protein in HEK-293 cells, cells were
transfected with PEI-MAX (Polysciences; Hirschberg an der Bergstrasse, Germany)
according to manufacturer’s instructions.
Retina staining. For retina staining, eyes were dissected and fixed in 4% PFA for
30 min on ice. Retinas were further dissected and permeabilized and blocked in 1%
BSA (Sigma, A4378) and 0.3% Triton X-100 overnight at 4 °C with gentle rocking.
Next, they were washed three times in Pblec buffer (1 mM CaCl2, 1 mM MgCl2, 1
mMMnCl2, and 1% Triton X-100 in PBS) and incubated with biotinylated isolectin
B4 (Vector, B-1205, Griffonia simlicifolia lectin I, 1:50) and primary antibodies,
overnight at 4 °C with gentle rocking: anti-c-Myc (Millipore 06-340, 1:100), anti-
ERG1/2/3 (Abcam 92513, 1:500), anti-FoxO1 (Cell Signaling 2880, 1:100), anti-
Claudin 5 (Zymed 341600, 1:100), anti-Collagen IV (Biorad 2150-1470, 1:400),
anti-phospho-aPKC (Abcam ab59412, 1:100) anti-VE-cadherin (eBioscience
555289, 1:200), anti-CD31 (BD biosciences 553370, 1:200), anti-podocalyxin (R&D
Systems AF1556, 1:200), anti-JAMA55, or anti-pSer218-FoxO1 (1:100). Polyclonal
anti-pS218 FoxO1 antibody was produced against Ile213-Arg-His-Asn-Leu-phos-
pho Ser218-Leu-His-Ser-Lys-Phe223 by Eurogentec (Köln Germany). Retinas were
washed five times with 0.5% BSA and 0.15% Triton X-100 and incubated with
Alexa-Fluor-coupled streptavidin (Invitrogen, 1:100) and the corresponding Alexa-
Fluor-coupled secondary antibody (Invitrogen, 1:500) in blocking buffer for 2 h at
room temperature. Nuclei were stained with DAPI (Sigma-Aldrich 1:1000) and
flat-mounted using Fluromount-G (SouthernBiotech, 0100-01). All images were
captured using a Leica SP-8 confocal microscope.
Phosphorylation assay. The reaction was carried out in a 50 µl assay mixture
containing 20 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 1 mM EGTA, 1 mM DTT, 0.2
µM recombinant aPKCλ (Millipore), 10 µM ATP, and 1 µM purified GST-FoxO1
b
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Fig. 6 aPKC expression level and FoxO1 phosphorylation status in patient
survival. a Kaplan–Meier survival curve of aPKC and b pSer218-FoxO1
expression in angiosarcoma patient samples. Mantel–Cox log rank test;
aPKC χ2= 3.866, df= 1 p= 0.0493; pSer218-FoxO1 χ2= 7.541, df= 1 p=
0.0060
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for 60 min at 30 °C. The reaction was stopped by the addition of SDS sample buffer
and the products were subjected to SDS-PAGE, followed by a CBB staining.
Radiolabeled bands were visualized with an image analyzer (Fuji BAS 4000).
Ultra high pressure liquid chromatography and mass spectrometry. Extracted
peptides from in-gel digestion were desalted, concentrated, and re-suspended in
acidified water (0.1 % formic acid). Peptides were separated on nanoLC 1000
(Proxeon, now Thermo Fisher) using a binary buffer system of A (0.1 % (v/v)
formic acid in H2O) and B (0.1 % (v/v) formic acid in 80% Acetonitrile)69. We
applied a linear gradient from 7 to 35% B for 35 min followed by 95% B for 15 min
and re-equilibration to 5% B within 5 min (held for further 5 min at 5 %) on a 50
cm column (75 µm ID) in-house packed with C18 1.8 µm diameter resin (Dr.
Maisch, Germany). To control the column temperature we used an in-house made
column oven at 40 °C. The UHPLC was coupled via a nano-electrospray ionization
source (Thermo Scientific) to the quadrupole based mass spectrometer QExactive
(Thermo Scientific)69. MS spectra were acquired using 3e6 as an AGC target at a
resolution of 70,000 (200m/z) in a mass range of 350–1650m/z. A maximum
injection time of 60 ms was used for ion accumulation. In a data dependent mode
MS/MS events were acquired for the ten most abundant peaks (Top10 method) in
the high mass accuracy Orbitrap after HCD (Higher energy C-Trap Dissociation)
fragmentation at 25 collision energy in a 100–1650m/z mass range. The resolution
was set to 17,500 at 200m/z combined with a maximum injection time of 60 ms.
For data analysis all 27 raw files were processed using MaxQuant (1.3.7.4) and
the implemented Andromeda search engine70. For protein assignment ESI-MS/MS
fragmentation spectra were correlated with the Uniprot human reference proteome
database including a list of common contaminants. Searches were performed with
Trypsin specificity allowing two missed cleavages and a mass tolerance of 4.5 ppm
and 7 ppm for MS/MS first and main searches, respectively. Carbamidomethyl at
cysteine residues was set as a fixed modification and phosphorylation (STY),
oxidation at methionine, and acetylation at the N-terminus were defined as variable
modifications. The minimal peptide length was set to 7 amino acids and the false
discovery rate for proteins and peptides to 1%. The FDR was applied separately for
modifications using the implemented decoy approach in revert mode. Identified
phosphorylation sites with specific scores and sequence windows are shown
(Supplementary Fig. 3A). Fold changes were calculated based on raw intensities.
Protein purification. The gene encoding full-length human FoxO1, full-length
human S218A FoxO1, wild-type human FoxO1 DNA-binding domain amino acids
151–266, and S218D human FoxO1 DNA-binding domain amino acids 151–266
proteins were sub-cloned into pDEST 15 (Thermo Scientific), produced in Rosetta
(DE3) Escherichia coli and purified on gluathione-Sepharose 4B beads (GE
Healthcare).
Phosphorylation assay in ECs. For transient overexpression of pCAGGS-myc-
aPKCλ and pcDNA3-FLAG-FoxO121 or empty vector control in HUVECs, DNA
was transfected into a 6-well plate using jetPEI (Polyplus; Illkirch, France)

























































































































































































































Fig. 7 aPKC and miR-34c control angiosarcoma proliferation. a Western blot analysis of c-Myc, pSer218-FoxO1, and total FoxO1 in ISO-HAS-B
angiosarcoma cells after treatment with aPKC inhibitor ATG for 24 h. Densitometric quantifications are shown below the lanes mean ±S.E.M.; one-way
ANOVA with Bonferroni post-hoc analyses; ***p < 0.001; (n= 3). b Relative BrdU incorporation in ISO-HAS-B cells after treatment with aPKC inhibitors
ATG, ATM, or aPKC kinase inhibitor after 24 h. Data represent mean ± S.E.M. two-tailed unpaired t-test **p < 0.01 (n= 6) cWestern blot analysis of c-Myc
expression in ISO-HAS-B cells after treatment with anti-miR-34c or scrambled control. Densitometric quantifications are shown below the lanes mean+ /-
S.E.M.; two-tailed unpaired t-test; (n= 3); *p < 0.05. d Relative BrdU incorporation in ISO-HAS-B cells after treatment with anti-miR-34c or scrambled
control. Data represent mean ± S.E.M. two-tailed unpaired t-test ****p < 0.0001 (n= 6). e Relative c-Myc expression measured by immunofluorescence in
FoxO1-CA or FoxO1-CA/D expressing cells compared to non-transfected neighboring cells; Data represent mean ± S.E.M.; one-way ANOVA with
Bonferroni post-hoc analysis; ns p > 0.05 vs. control; *p < 0.05 CA vs. CA/D; ***p < 0.01 vs. control. f Relative EdU incorporation in FoxO1-CA or FoxO1-
CA/D expressing cells compared to non-transfected neighboring cells; Data represent mean ± S.E.M. one-way ANOVA with Bonferroni post-hoc analysis;
**p < 0.01 CA vs. CA/D; ***p < 0.01 vs. control, ****p < 0.001 vs. control
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cells were washed with PBS and harvested with SDS sample buffer. Samples were
subjected to western blot analysis with anti-pSer218-FoxO1, anti-Myc (No. sc-40;
Santa Cruz Biotechnologies; Heidelberg, Germany), and anti-Flag-M2 antibodies
(No. F1804; Sigma)
Nuclear fractionation. HUVECs were lysed 48 h post siRNA KD or 24 h after
transfection of pCAGGS-myc-aPKCλ and pcDNA3-FLAG-FoxO1 in a hypotonic
buffer (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and 0.05 % NP-
40) and then centrifuged for 10 mins at 16,000× g at 4 °C. The supernatant
representing the cytoplasmic fraction was collected and the pellet was washed twice
with the hypotonic buffer. Pellets were then re-suspended and lysed in a high salt
buffer (450 mM NaCl, 50 mM Tris pH 7.5, 2 mM DTT, 1% NP-40, protease
inhibitor (Sigma P2714), and phosphatase inhibitor (Calbiochem 524629; Darm-
stadt, Germany) and incubated for 10 min with rotation at 4 °C. Following cen-
trifugation at 16,000× g for 15 min the supernatant was collected and snap frozen at
−80 °C. For normalization of loading, a BCA protein assay (Pierce; Schwerte,
Germany) was carried out and 16 μg of protein was loaded onto the gel in 6xSDS
loading buffer and western blot analysis was carried out according to standard
laboratory practices. Western blot analysis of fractionated samples was carried out
with the following antibodies: anti-FoxO1 (Cell Signaling Technology; No. 2880),
anti-Lamin A/C (Santa Cruz Biotechnologies; No. sc-6215), anti-Lamin B1 (Santa-
Cruz Biotechnologies; No. sc-6216), anti-α-tubulin (Cell Signaling Technology; No.
2125), anti-aPKC (BD Biosciences; No. 610207), or phospho-aPKC (Abcam;
ab59412).
DNA-binding Assay. EMSAs were performed with biotinylated DNA duplexes
containing the DBE sequence strands 5′–CAAAATGTAAACAAGA-3′ and 5′-
TCTTGTTTACATTTTG-3′ (Sigma). Complementary strands of duplex DNA
were annealed in 20 mM HEPES (pH 7.5) and 50 mM NaCl buffer by heating to 80
°C for 10 min and then slowly cooling to room temperature for 3 h. WT-FoxO1 or
S218D-FoxO1 DNA-binding domain at a final concentration of 1 µM were mixed
with 1 nM of DNA and incubated at RT for 30 min in binding buffer containing 20
mM Tris (pH 8.0), 50 mM KCl, 5% glycerol, 2 mM DTT, 0.2 mM EDTA, 2 mM
MgCl2, 0.1 mg/mL BSA, and 1 ng/mL poly dI-dC. The mixture was then loaded
onto a 6% DNA retardation gel in 0.5X TBE and run at 100 V for 1 h at 4 °C. The
gel was then blotted to a Biodyne B membrane (Invitrogen) at 380 mA for 1 h in
0.5X TBE at 4 °C. The DNA was cross-linked to the membrane using a Stratagene
cross-linker and developed using the chemiluminescent nucleic acid detection kit
(Pierce) according to manufacturers instructions.
Chromatin-immunoprecipitation. HUVEC were transfected with pcDNA3-
FLAG-FoxO1-3A21 constitutively active mutant, pcDNA3-FLAG-FoxO1-3A-
S218D mutant or empty vector control and 24 h after transfection 10 × 106 cells
were fixed for 30 seconds with 3% formaldehyde and cross-linking was stopped
with 2.5 M glycine. Cells were lysed in lysis buffer (5 mM PIPES; 85 mM KCl; 0.5%
NP-40; Protease inhibitor (Sigma)) and nuclei were isolated by passing lysate
through a 27 g needle. Nuclei were then sheared using a Bioruptor sonicator for
2 × 10 cycles (30 s on/off) in RIPA buffer to a size of 200–300 bp. Sheared chro-
matin was then incubated with FLAG-M2-conjugated Protein-G Dynabeads
(Sigma and Invitrogen). Cross-links were reversed by overnight incubation at 65 °C
followed by Proteinase-K treatment at 37 °C for 1 h and cleaned up with the
Qiaquick PCR clean up kit. Precipitated chromatin and inputs were amplified by
quantitative PCR.
Luciferase assays. HEK293 cells were transfected with pGL3-6xDBE and pGL4-
hRluc and 8 h post transfection cells were washed with PBS and medium was
replaced or changed to DMEM+ 0.1% BSA with or without 5 µM aPKC kinase
inhibitor (539624, Calbiochem) and incubated overnight. For experiments using
the CTDSP2/CTDSP2-mut luciferase constructs, luciferase vectors20 and pGL4-
hRluc were transfected with vector controls and pCAGGS-myc-aPKCλ and wild-
type pcDNA3-FLAG-FoxO1. pGL3-6xDBE and pGL4-hRluc were also co-
transfected with either pcDNA3-FLAG-FoxO1-3A mutant or pcDNA3-FLAG-
FoxO1-3A-S218D mutant. All experiments were collected 24 h post transfection
and luciferase and Renilla expression were measured using the Dual-Luciferase
Reporter Assay (Promega) using a Mithras LB940 plate reader (Berthold Tech-
nologies), according to the manufacturers instructions and luciferase luminescence
was normalized for input to Renilla luminescence.
RNA extraction and qPCR analysis and western blotting. For analysis of
messenger RNA expression levels total RNA was isolated from HUVEC using the
Quick RNA-Mini kit (Zymo Research; Freiburg, Germany) and from control or
mutant retinas using the RNeasy Mini Kit (Qiagen). A volume of 0.5–1 μg of RNA
was used per reaction to generate cDNA with the Superscript VILO cDNA
synthesis kit (Invitrogen; HUVEC) or iScript cDNA synthesis Kit (Bio-rad; reti-
nas). qPCR was carried out using a StepOnePlus real time PCR machine using in-
house designed primers or pre-made primer sets (Applied Biosystems, Calsbad,
CA). Sequences of pre-made primers and in-house designed primers are shown in
supplementary table 3. TaqMan gene expression assay for PKM2 and Cldn5 were
used in combination with TaqMan Fast Gene Expression Master Mix (Applied
Biosciences) and expression was normalized to endogenous GAPDH also using the
Taqman gene expression assay. Primer information is shown in supplementary
table 4. All other targets were analyzed using SYBR-Green PCR Master Mix
(Applied Biosystems). Gene expression assays carried out using SYBR-Green were
normalized to endogenous expression of B2M.
Samples for western blotting were collected into 1xSDS-sample buffer and
subjected to immunoblotting with anti-c-Myc (Santa Cruz Biotechnology; sc-40 or
Millipore; 06-340), anti-FLAG (Sigma; 8592); anti-aPKC (BD Biosciences; 610207),
or in-house prepared pSer218-FoxO1 and normalized to anti-α-tubulin (Cell
Signaling Technology; 2125). See example uncropped blots in the Supplementary
figure 11.
For western blot analysis from the formalin-fixed paraffin embedded
angioscaroma patient sample, five 10 μm sections were freshly cut and placed in a
tube. The sections were first deparaffinized with xylene and then rehydrated in a
graded alcohol series and allowed to air dry. Subsequently, a 300 mM Tris-HCl pH
8.0 and 2% SDS solution was added to the tube and incubated for 5 min at room
temperature. The samples were then sonicated in a Bioruptor ultrasonicator for 2 ×
30 sec and boiled at 100 °C for 20 min. The samples were further incubated at 80 °C
for 2 h and then centrifuged for 20 min at 16,000× g. 6x SDS sample buffer was
then added to the supernatant and samples were then boiled again for 10 min and
loaded onto the gel.
miRNA extraction and qPCR analysis. Total small RNAs from HUVEC, ISO-
HAS-B, and mouse retina were collected using the mirVANA miRNA isolation kit
(Ambion) or miRNeasy mini kit (Qiagen). For isolation of miRNA after aPKC
inhibitor treatment, HUVEC or ISO-HAS-B were incubated overnight in EBM+
0.1% BSA with or without 5 µM aPKC kinase inhibitor (539624, Calbiochem) or
sodium aurothioglucose (ATG; Sigma). The reverse transcription reaction was
carried out using 10 ng of total small RNAs and the TaqMan advanced miRNA
cDNA synthesis kit (Applied Biosystems).
miR-34c-5p and miR-145-5p expression were analyzed with TaqMan Advance
miRNA assays and expression was normalized to miR-186-5p control. Sequences
of primers are shown in Supplementary Table 4.
In vivo anti-miR treatment. PrkciiΔEC pups were injected intra-abdominally on P1
and P3 with either anti-miR-34c-5p or anti-miR scrambled control miRCURY
LNA Pwr inhibitor (Exiqon) at a final dose of 10 mg/Kg. Phenotype was analyzed
at P6 and tamoxifen injected Cre− littermates were used as controls.
In vitro cell proliferation assay. HUVEC, ISO-HAS-B, and AS-M were re-seeded
onto triplicate wells in a 96 well plate at a density of 5000 or 10,000 cells per well.
Cells were incubated overnight or for 24 h with or without aPKC kinase inhibitor,
sodium aurothioglucose (ATG, Sigma), or sodium aurothiomalate hydrate (ATM,
Sigma) and then BrdU was added to the culture medium and the cells were
incubated for a further 2 h. BrdU incorporation was then detected using the Cell
proliferation ELISA colorimetric kit (Roche; 11647229001).
Alternatively, ISO-HAS-B cells were grown on gelatin-covered coverslips and
subsequently transfected with either scrambled control or FoxO1 siRNA or FoxO1-
CA or FoxO1-CA/D. Twenty four hours post FoxO1, siRNA transfection medium
was changed to medium with or without aPKC kinase inhibitor and the cells were
incubated for a further 24 h. Two hours before the end of the incubation period
(24 h for FoxO1 mutant overexpression and 48 h for FoxO1 siRNA), EdU was
added to the cell culture medium according to the manufacturer’s instructions and
EdU incorporation was examined using the Click-ItTM EdU Alexa Fluor 488
Imaging Kit (Invitrogen). Nuclei were visualized with Hoescht 33342. To identify
cells expressing FoxO1-CA/FoxO1-CA/D, after the completion of the Click-ItTM
reaction cells were stained with anti-FLAG-M2 (1:400; Sigma) overnight at 4 °C,
followed by washing and incubation with Alexafluor donkey-anti-mouse 555 and
finally Hoescht 33342. The proportion of FLAG positive EdU positive cells was
compared to the proportion of FLAG negative EdU positive neighboring cells.
Immunofluorescent staining of HUVEC and ISO-HAS-B cells. HUVEC and
ISO-HAS-B cells were cultured on gelatin coated coverslips and were either left
untreated or transfected for ectopic expression of FoxO1 mutants. Cells were fixed
for 10 min with 4% paraformaldehyde, washed with PBS and then permeabilized
with 0.5% Triton-100 × -PBS for 10 min. Subsequently cells were blocked with 5%
FCS 0.01% Tween-20-PBS for 30 min followed by incubation with anti-aPKC
(1:100; Beckton Dickison), anti-VE-cadherin (1:100; R&D Systems); anti-c-Myc
(1:100; Millipore); and anti-FLAG-M2 (1:400; Sigma) overnight at 4°C. Coverslips
were then washed and incubated with the appropriate secondary antibodies
(Alexafluor fluorescently conjugated; 1:400; Invitrogen) and Hoescht 33342 or
DAPI, and mounted with Vectashield.
Angiosarcoma and pyogenic granuloma tissue sample immunostaining.
Formaldehyde-fixed paraffin block patient tissue samples were cut into 5-7 μM
sections then deparaffinized in xylene and rehydrated in a graded ethanol series.
This was followed by antigen retrieval in sodium citrate buffer by boiling the slides
for 15 min. The tissue was then blocked in 5% FCS+ 0.1% Tween-20 for 30 min at
room temperature followed by incubation with primary antibodies overnight at 4
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degrees (anti-FoxO1 1:100; Abcam 39670; anti-c-Myc 1:50; Millipore 06-340; anti-
aPKC 1:25; Becton Dickinson; 610207; anti-pSer218-FoxO 1:100; in-house pre-
paration; anti-VE-Cadherin 1:100; R&D Systems AF938; anti-Ki67 1:100; Abcam
15580). Tissue was then washed and secondary antibodies were applied. For rabbit
primary antibodies (FoxO1, c-Myc, pSer218-FoxO), tissue was first incubated for 1
h at room temperature with biotin-conjugated donkey-anti-rabbit (Jackson
Immunoresearch 1:200; 711-065-152), then washed and incubated with donkey-
anti goat and streptavidin conjugated secondary antibodies (Invitrogen 1:200)
again for 1 h. For anti-aPKC mouse antibody double staining with anti-VE-Cad-
herin, slides were first incubated with donkey-anti goat secondary (Invitrogen
1:200) for 1 h at room temperature, followed by goat-anti mouse secondary
(Invitrogen 1:200) for an additional hour. All slides were then incubated with
Hoechst 33342. Ki67 index was calculated as the proportion of Ki67 positive VE-
Cadherin positive cells in a tissue section and samples were classified as Ki67 high
when the Ki67 index was above the average calculated for the samples and low
when below average. Staining intensity and localization were evaluated by three
investigators independently.
c-Myc fluorescent in-situ hybridization. The presence of c-Myc gene amplifi-
cation was examined in c-Myc overexpressing patient samples using the kit
Zytolight SPEC CMYC/CEN 8 dual color probe (Zytovision; Bremerhaven, Ger-
many) and Zytolight FISH-Tissue implementation Kit (Zytovision) according to
manufacturer’s instructions.
Quantification and Image processing. Data are based on at least three inde-
pendent experiments or three mutant and control animals for each stage and result
shown. The data are presented as mean ±S.E.M. and exact statistical analyses
carried out are detailed in the figure legends. All statistical analyses were carried out
using Prism 5 software. A p < 0.05 was considered significant.
Volocity (Improvision) was used for quantitative image analysis. Volocity,
Photoshop CS, and Illustrator CS (Adobe) software were used for image processing
and in compliance with general guidelines for image processing.
The authors can confirm that all relevant data are included in the paper or its
supplementary information files.
Data availability
The remaining data are available within the article and its supplementary infor-
mation files and from the corresponding author on reasonable request. The mass
spectrometry proteomics data have been deposited in the ProteomeXchange
Consortium via the PRIDE partner repository under the accession code
PXD011595.
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